Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Acro Biomedical (ACBM) EPS (Weighted Average and Diluted) (2020 - 2025)

Acro Biomedical (ACBM) has 6 years of EPS (Weighted Average and Diluted) data on record, last reported at $0.0 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 498.44% year-over-year to $0.0; the TTM value through Dec 2025 reached -$0.0, down 139.13%, while the annual FY2025 figure was -$0.0, 139.13% down from the prior year.
  • EPS (Weighted Average and Diluted) reached $0.0 in Q4 2025 per ACBM's latest filing, up from -$0.0 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.04 in Q4 2021 and bottomed at -$0.07 in Q1 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.02, with a median of -$0.0 recorded in 2025.
  • Peak YoY movement for EPS (Weighted Average and Diluted): soared 3294.2% in 2021, then tumbled 1051.72% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.04 in 2021, then crashed by 245.23% to -$0.06 in 2022, then soared by 99.49% to -$0.0 in 2023, then skyrocketed by 41.49% to -$0.0 in 2024, then skyrocketed by 498.44% to $0.0 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were $0.0 in Q4 2025, -$0.0 in Q3 2025, and -$0.0 in Q2 2025.